EA201391348A8 - КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА - Google Patents

КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА

Info

Publication number
EA201391348A8
EA201391348A8 EA201391348A EA201391348A EA201391348A8 EA 201391348 A8 EA201391348 A8 EA 201391348A8 EA 201391348 A EA201391348 A EA 201391348A EA 201391348 A EA201391348 A EA 201391348A EA 201391348 A8 EA201391348 A8 EA 201391348A8
Authority
EA
Eurasian Patent Office
Prior art keywords
disease
alpha
dyskinesia
dopkinom
carostern
Prior art date
Application number
EA201391348A
Other languages
English (en)
Other versions
EA201391348A1 (ru
Inventor
Дональд Джонс
Тересе Ди Паоло
Доминик Фойербах
Бальтазар Гомес-Манкилла
Кристина Лопес-Лопес
Фабрицио Гаспарини
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201391348A1 publication Critical patent/EA201391348A1/ru
Publication of EA201391348A8 publication Critical patent/EA201391348A8/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Изобретение относится к новым комбинациям, применимым для лечения дискинезии, связанной с лечением болезни Паркинсона агонистом допамина, включающая в качестве активных ингредиентов по меньшей мере один обладающий низкой молекулярной массой активатор никотинового ацетилхолинового рецептора альфа-7 и по меньшей мере один обладающий низкой молекулярной массой антагонист метаботропного глутаматного рецептора 5; к их получению; к их применению в качестве лекарственных средств и к содержащим их лекарственным средствам.
EA201391348A 2011-03-18 2012-03-16 КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА EA201391348A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161454378P 2011-03-18 2011-03-18
PCT/IB2012/051282 WO2012127393A1 (en) 2011-03-18 2012-03-16 COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE

Publications (2)

Publication Number Publication Date
EA201391348A1 EA201391348A1 (ru) 2014-01-30
EA201391348A8 true EA201391348A8 (ru) 2014-11-28

Family

ID=45937485

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391348A EA201391348A8 (ru) 2011-03-18 2012-03-16 КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА

Country Status (11)

Country Link
US (1) US20140228398A1 (ru)
EP (1) EP2685977A1 (ru)
JP (1) JP6031458B2 (ru)
KR (1) KR20140018286A (ru)
CN (1) CN103561740A (ru)
AU (1) AU2012232711B2 (ru)
BR (1) BR112013023813A2 (ru)
CA (1) CA2830458A1 (ru)
EA (1) EA201391348A8 (ru)
MX (1) MX2013010698A (ru)
WO (1) WO2012127393A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
JP6461150B2 (ja) * 2013-07-31 2019-01-30 ノバルティス アーゲー １，４−二置換ピリダジン誘導体およびｓｍｎ欠損に関連する状態を処置するためのその使用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AU2002340470A1 (en) * 2001-11-13 2003-05-26 Teva Pharmaceutical Industries, Ltd. L-dopa ethyl ester salts and uses thereof
DE10156719A1 (de) 2001-11-19 2003-05-28 Bayer Ag Heteroarylcarbonsäureamide
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
DE10211415A1 (de) 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
DE10211416A1 (de) 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10234424A1 (de) 2002-07-29 2004-02-12 Bayer Ag Benzothiophen-, Benzofuran- und Indolharnstoffe
GB0220581D0 (en) * 2002-09-04 2002-10-09 Novartis Ag Organic Compound
RU2391341C2 (ru) 2002-09-25 2010-06-10 Мемори Фармасьютиклз Корпорейшн Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение
EP2028180A1 (en) 2003-03-04 2009-02-25 ADDEX Pharma S.A. Novel aminopyridine derivatives as mGluR5 antagonists
UA80888C2 (en) 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US20050245531A1 (en) 2003-12-22 2005-11-03 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US7585881B2 (en) 2004-02-18 2009-09-08 Astrazeneca Ab Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
EP1756086B1 (en) 2004-06-01 2008-06-04 F.Hoffmann-La Roche Ag Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists
GB0413605D0 (en) 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
JP2008523058A (ja) 2004-12-10 2008-07-03 アボット・ラボラトリーズ 縮合ビシクロ複素環置換キヌクリジン誘導体
AR058807A1 (es) 2005-09-29 2008-02-27 Astrazeneca Ab 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TW200813067A (en) 2006-05-17 2008-03-16 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
ES2525076T3 (es) 2006-05-19 2014-12-17 Abbvie Bahamas Ltd. Derivados de alcanos azabicíclicos sustituidos con bicicloheterociclos condensados activos en el SNC
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
AU2007336369B2 (en) 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
EP2322166A1 (en) * 2007-04-02 2011-05-18 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
MX2009011208A (es) * 2007-04-19 2009-10-30 Novartis Ag Derivados de acido nicotinico como moduladores del receptor de glutamato metabotropico-5.
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
CN101854935A (zh) 2007-10-12 2010-10-06 诺瓦提斯公司 用于治疗帕金森氏病的代谢型谷氨酸受体调节剂
AR068921A1 (es) 2007-10-19 2009-12-16 Astrazeneca Ab Derivados heterociclicos de tetrazol y 1,2-4 triazoles, composiciones farmaceuticas que los contienen y usos de los mismos para tratar desordenes neurologicos, gastrointestinales y del dolor,entre otros.
WO2009066107A1 (en) 2007-11-21 2009-05-28 Astrazeneca Ab Use of a nicotinic receptor agonist
US8377941B2 (en) * 2008-04-17 2013-02-19 Proximagen Limited Indoles as modulators of nicotinic acetylcholine receptor subtype alpha-7
WO2010043515A1 (en) 2008-10-13 2010-04-22 F. Hoffmann-La Roche Ag Diazonium-free method to make an indazole intermediate in the synthesis of bicyclic 5-(trifluormethoxy)-1h-3-indazolecarboxylic acid amides
WO2010056622A1 (en) 2008-11-11 2010-05-20 Targacept, Inc. TREATMENT WITH ALPHA α7-SELECTIVE LIGANDS
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102573842A (zh) * 2009-07-23 2012-07-11 诺瓦提斯公司 氮杂双环烷基衍生物或吡咯烷-2-酮衍生物的用途
JO3250B1 (ar) * 2009-09-22 2018-09-16 Novartis Ag إستعمال منشطات مستقبل نيكوتينيك أسيتيل كولين ألفا 7

Also Published As

Publication number Publication date
CA2830458A1 (en) 2012-09-27
AU2012232711A1 (en) 2013-10-03
AU2012232711B2 (en) 2016-04-28
US20140228398A1 (en) 2014-08-14
JP2014508188A (ja) 2014-04-03
KR20140018286A (ko) 2014-02-12
EP2685977A1 (en) 2014-01-22
MX2013010698A (es) 2014-02-17
CN103561740A (zh) 2014-02-05
EA201391348A1 (ru) 2014-01-30
BR112013023813A2 (pt) 2016-12-13
JP6031458B2 (ja) 2016-11-24
WO2012127393A1 (en) 2012-09-27

Similar Documents

Publication Publication Date Title
CY1123365T1 (el) Ενωσεις που εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
CY1116892T1 (el) Ενωσεις οι οποιες εχουν δραστικοτητα ανταγωνιστη μουσκαρινικου υποδοχεα και αγωνιστη βητα2 αδρενεργικου υποδοχεα
MX2009006304A (es) Nuevos compuestos de oxadiazol.
CY1117696T1 (el) ΝΕΑ ΠΑΡΑΓΩΓΑ ΚΥΚΛΟΕΞΥΛΑΜΙΝΗΣ ΜΕ ΔΡΑΣΕΙΣ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΑΓΩΝΙΣΤΗ ΚΑΙ Μ3 ΜΟΥΣΚΑΡΙΝΙΚΟΥ ΑΝΤΑΓΩΝΙΣΤΗ
CY1119798T1 (el) Μορφη iv υδροχλωρικης ιβαμπραδινης
BR112015000704A2 (pt) imidazotriazinacarbonitrilas úteis como inibidores de quinase
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
PH12015501339A1 (en) Indole carboxamide derivatives as p2x7 receptor antagonists
NO20083630L (no) Nye pyridinderivater
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
MY171899A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
MX2014004433A (es) Nuevos derivados de ciclohexilamina que tienen actividad como agosnitas adrenergicos beta 2 y como antagonistas muscarinicos m3.
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
GEP201606526B (en) 5-ht3 receptor antagonists
PH12014501415A1 (en) Heterocyclic amide derivatives as p2x7 receptor antagonists
MX2013002329A (es) Agonista de receptores de neutrofina y sus usos como medicamentos.
PH12014502366A1 (en) Injectable formulation
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
MX2013008197A (es) Sales de aminas organicas de azilsartan, metodo de preparacion y uso de las mismas.
MY176244A (en) Crystalline salt form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1-yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone as orexin receptor antagonist
EA201300857A1 (ru) Пиразолы в качестве антагонистов crth2
EA201391348A8 (ru) КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
ATE482195T1 (de) Benzoäfüisoindole als antagonisten des ep4- rezeptors
PE20130813A1 (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity